Substack spotlights Ruxandra Teslo

- On September 2, 2026, Substack highlighted biotech writer Ruxandra Teslo in a post showcasing specialist, newsletter-led science writing on drug development and policy. (substack.com) - Teslo’s Substack says she is a writer at Works in Progress and co-founder of Clinical Trial Abundance, with 14K+ subscribers shown on profile pages. (substack.com) - Readers can find Teslo’s archive on Substack, including posts on Eroom’s Law, clinical trials, FDA policy and biotech productivity. (writingruxandrabio.com)

Substack used a September 2 post to spotlight biotech writer Ruxandra Teslo as an example of the kind of specialist, email-first work it wants to surface on the platform. Teslo writes on drug development, clinical trials and science policy, and her Substack archive includes essays on Eroom’s Law, FDA decisions and the limits of AI in speeding drug discovery. (substack.com) Her profile describes her as a writer at Works in Progress, a co-founder of Clinical Trial Abundance and a scientist by training. The post matters because it shows Substack promoting a writer whose pitch is not general-interest commentary but domain-specific analysis. (writingruxandrabio.com) Teslo’s Substack describes itself as “pro-progress, anti-safetyist commentary” from a genomics PhD, and the archive shows that the publication has built around recurring biotech and policy themes rather than a broad personal blog format. ### Who is Ruxandra Teslo, and what does her Substack say she covers? Ruxandra Teslo’s Substack profile says she is a writer at Works in Progress and co-founder of Clinical Trial Abundance. Her “About” page says she writes on scientific and cultural matters from the perspective of a genomics PhD. (substack.com) Her archive shows a consistent concentration on biotech productivity, clinical-trial design and regulation. Recent and archived posts include “A manifesto for reviving biopharma productivity,” “A response to Dario Amodei on AI & clinical trials,” and “The FDA should not change its mind last minute.” (writingruxandrabio.com) ### Why did Eroom’s Law become part of the example? Teslo’s archive includes a December 2025 post framed around Eroom’s Law, which she described as a problem in biopharma productivity. A separate note on her Substack said AI would not remove the “cost and time drag of clinical trials,” underscoring the same focus on drug-development bottlenecks. (substack.com) An essay published by Asimov Press identified Teslo as a fellow at Renaissance Philanthropy and co-founder of the Clinical Trial Abundance project, and said she had co-authored work arguing that more efficient clinical trials are essential to breaking Eroom’s Law. (writingruxandrabio.com) ### What does Substack appear to be emphasizing by choosing her? Substack’s choice of Teslo points to a model built around subject-matter authority, recurring themes and a recognizable newsletter voice, based on the material visible on her profile and archive. Her publication description promises a stable lens — genomics, biotech, culture and policy — rather than a rotating mix of unrelated topics. (writingruxandrabio.com) The profile pages also show audience scale as part of that pitch. Substack’s profile for Teslo shows more than 14,000 subscribers, while her publication landing page says it has tens of thousands of subscribers. (press.asimov.com) ### Why is this useful as a case study for other writers? Teslo’s archive gives writers a clear example of how a newsletter can build trust through repetition and depth. The posts return to a narrow set of issues — clinical trials, biotech productivity, FDA decisions and scientific progress — with enough continuity that readers know what kind of argument and reporting they are likely to get. (writingruxandrabio.com) Works in Progress, where Teslo is listed as a writer, describes itself as a publication for “new and underrated ideas to improve the world.” That affiliation fits with the tone and subject matter of her Substack and helps explain why Substack could present her as a platform-native example of specialist long-form work. (substack.com) ### Where can readers see the pattern for themselves? Teslo’s archive page remains the clearest place to see the structure of the publication. The listed posts span biotech productivity, AI and clinical trials, FDA decision-making and broader science-policy arguments, all under the same byline. (writingruxandrabio.com) Her Substack profile and publication pages also list her role, publication description and subscriber figures. Those pages, along with her Works in Progress affiliation and the Clinical Trial Abundance references in outside essays, are the next checkpoints for anyone tracing how Substack is presenting specialist newsletter writers on September 2. (worksinprogress.news) (substack.com) (writingruxandrabio.com)

Get your own daily briefing

Scout delivers personalized news, insights, and conversations tailored to your role and industry.

Download on the App Store

Shared from Scout - Be the smartest in the room.